Aptamer Group Limited, the developer of custom affinity tools to enable the life science industry through its proprietary Optimer™ platform, today announces that it has entered into a commercial agreement with a public life science research tool company to develop Optimer ligands for use on their platform.
Under the terms of the agreement, Aptamer Group will develop Optimer ligands to be integrated into its partner’s life science research platform. The deal structure includes phased project payments potentially totalling multiple millions of pounds, with IP-related milestone payments and long-term single-digit royalty payments.
Optimer ligands are nucleic acid-based affinity ligands that can be used as an antibody alternative to enable novel solutions across the life sciences. The Optimer platform consists of three parallel discovery processes that are optimised for specific target types from small molecules to proteins and cells, for increased success in the discovery and development of high affinity, high specificity Optimer ligands.
“We are excited to be enabling this novel life science research platform with our Optimer ligands to help our partner maximise its potential as a truly revolutionary tool in biomedicine. For Aptamer Group, this deal represents a significant milestone owing to the significant commercial rewards, reflecting our partners’ growing confidence in the platform. We are proud be applying the Optimer platform to offer new advances that may hold the key to improvements for researchers and patients worldwide.”
Dr Arron Tolley, Chief Executive Officer of Aptamer Group
To discover more, please visit our website- https://aptamergroup.com/news/